CSI Market
Sign In | Register

Global Blood Therapeutics (GBT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GBT Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Global Blood Therapeutics funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2022)
6 Months 		(Mar 31 2022) (Dec 31 2021) (Sep 30 2021) (Jun 30 2021)
Operating Activities
Income-163.89
Depreciation & amortization3.05
Amortization of Other Assets1.54
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-6.81
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation38.98
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Operating Lease Right Of Use Asset Amortization-
Gain Loss On Modification Of Lease-
Operating Lease Right Of Use Asset Amortization Expense1.52
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-3.49
Increase (Decrease) in Accounts Payable, Trade-6.84
Increase (Decrease) in Other Accrued Liabilities13.97
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.98
Other Working Capital5.48
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.65
Discontinued operations0.00
Net Cash flow from Operating Activities-116.16
Investing Activities
Capital Expenditures-0.64
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities29.50
Payments to Acquire Marketable Securities-386.03
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-357.16
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock48.50
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.10
Payments For Repurchase Of Shares Under Incentive And Share Based Compensation Plans Excluding Stock Options-
Proceeds From Exercise Of Stock Options And E S P P2.80
Proceeds From Issuance Of Convertible Debt Net-
Payment For Purchases Of Capped Call Options-
Accrued Issuance Costs Incurred During Non Cash Or Partial Non Cash Transaction-
Accrued Purchases Of Property And Equipment0.01
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities50.20
Effect of exchange rate on cash flow-0.45
Discontinued operations0.00
Free Cash Flow-116.80
Total Cash Flow-423.57
4 historic quarters locked

Sign in to unlock the full Global Blood Therapeutics cash flow history.

Sign In Create Free Account

About Global Blood Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-22-015231

Figures are derived from filed reports and may be restated. Historical data is subject to revision.